Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: Disitamab vedotin — recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks

Primary Outcomes

  • Progression-Free Survival (From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-08
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Disitamab vedotin — recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed breast cancer; * Prior or current use of Disitamab vedotin (RC48-ADC); Exclusion Criteria: * Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Conditions Non-small Cell Lung Cancer, Head and Nec...
Phase PHASE1
Enrollment 45
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: NT-175 — * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide * Single infusion Autologous, engineered T Cells targeting TP53 R175H * Post-infusion recombinant interleukin-2 (rIL-2)

Primary Outcomes

  • Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours (28 days after infusion)
  • Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours (Up to 24 months post-infusion)
  • Module 1, Part 2: Preliminary anti-tumour activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours (Up to 24 months after infusion)
  • Module 2: Safety of NT-175 in participants with haematological malignancies (Up to 28 days after infusion)
  • Module 2: Safety of NT-175 in participants with haematological malignancies (Up to 24 months after infusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-07-12
Completion: 2029-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • AstraZeneca (STUDY_DIRECTOR) - AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Biological: NT-175 — * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide * Single infusion Autologous, engineered T Cells targeting TP53 R175H * Post-infusion recombinant interleukin-2 (rIL-2)
Study Locations (23 sites)
Research Site, Gilbert, Arizona 85234 United States
Research Site, Duarte, California 91010 United States
Research Site, Duarte, California 91010 United States
Research Site, Los Angeles, California 90095 United States
Research Site, Newport Beach, California 92663 United States
Research Site, Santa Monica, California 90404 United States
Research Site, Jacksonville, Florida 32224 United States
Research Site, Miami, Florida 33136 United States
Research Site, Tampa, Florida 33612 United States
Research Site, Boston, Massachusetts 02115 United States
Eligibility Criteria
Key Inclusion Criteria (Module 1) * Subjects must be at least 18 years of age * Subject must be diagnosed with one of the histologies below: * NSCLC * Colorectal adenocarcinoma * HNSCC * Pancreatic adenocarcinoma * Breast cancer * Ovarian cancer * Any other solid tumor * Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A\*02:01 positive (at least 1 allele) * Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options. * Subject has at least 1 measurable lesion * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Adequate hematological, renal, hepatic, pulmonary, and cardiac function Key Exclusion Criteria (Module 1) * Any another primary malignancy within the 3 years prior to enrollment * Known, active primary central nervous system (CNS) malignancy * History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation. * History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment. * Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment. * Any form of primary immunodeficiency. * Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome. Key Inclusion Criteria (Module 2 - hematological malignancies) * At least 18 years of age * Diagnosis of AML or MDS that allows for efficacy assessments * Confirmation of TP53 R175H variant mutation in cancer cells * Subject must be HLA-A\*02:01 positive (at least 1 allele) * ECOG performance status of 0 to 1 Key Exclusion Criteria (Module 2 - hematological malignancy) * Acute promyelocytic leukaemia or isolated extramedullary disease * Another primary malignancy within 2 years (with exceptions) * HSCT within 100 days or immunosuppression for GvHD within 4 weeks * History of CNS or other extramedullary leukaemic involvement unless a lumbar puncture is negative for leukemic cells * Prior stroke, ischemic attack, significant cardiac disease, heart failure * Prior adoptive modified cell therapy * Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.
Conditions Depression, Anterior Cruciate Ligament I...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this parallel arm prospective randomized control trial study is to compare outcomes in Anterior Cruciate Ligament Reconstruction (ACLR) Surgery patients after exposure to a virtual psychological intervention (VPI) versus standard care. The main question the investigators are asking is if virtual administration of psychological CBT modules will be an accessible and convenient vehicle to improve ACLR outcomes. Participants will be placed either into a treatment group receiving virtual modules of cognitive behavioral therapy in addition to standard of care ACLR surgery or the control group receiving only the standard of care ACLR surgery. The investigators hypothesize that ACLR patients in the VPI cohort will have improved return to sport and post operative outcomes compared to controls.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Virtual Psychological Intervention: Cognitive Behavioral Therapy — An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.

Primary Outcomes

  • Number of patients who Return to Sport at time set-points (3,6,12 and 24 months)
  • Patient-Reported Outcome Measurement Information System (PROMIS) scores for Physical Function and Pain Interference (3,6,12, and 24 months)
  • Patient Health Questionnaire-2 (PHQ-2) scores (3,6,12, and 24 months)
  • ACL-Return to Sport after Injury (ACL-RSI) scores (3,6,12 and 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2027-03
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henry Ford Health System
Principal Investigators:
  • Thomas Sean Lynch, MD (PRINCIPAL_INVESTIGATOR) - Henry Ford Health System
Contact Information
Study Contact:
Maxim Jani, BS
2488240579
mjani1@hfhs.org
Maxim Jani, BS
2488240579
mjani1@hfhs.org
Henry Ford Health System
Interventions
  • Behavioral: Virtual Psychological Intervention: Cognitive Behavioral Therapy — An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
Study Locations (1 sites)
Henry Ford Health System, Detroit, Michigan 48202 United States
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 12 with ACL injuries undergoing ACLR with a Henry Ford Sports Orthopedic Surgeon * First time ACLR on the injured knee Exclusion Criteria: * Patients undergoing revision ACL surgery * Concomitant posterior cruciate ligament injury of the involved knee * Systemic or local infection pre-operatively * Systemic administration of any type of corticosteroid or immunosuppressive agents within 30 days of surgery * History of rheumatoid arthritis, inflammatory arthritis, or autoimmune diseases * Pregnancy
Conditions Breast Cancer, Lymphoma
Phase EARLY_PHASE1
Enrollment 104
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Device Feasibility Masking/blinding: Triple

Interventions / Regimen

  • Device: PARASYM neuromodulation device — Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
  • Device: PARASYM neuromodulation device — Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the "experimental arm" for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.

Primary Outcomes

  • Effects of low-level tragus stimulation (LLTS) on global longitudinal strain (GLS) (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-12-01
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oklahoma
Principal Investigators:
  • Tarun W. Dasari, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of Oklahoma
Contact Information
Study Contact:
SCC IIT Office
4052718777
SCC-IIT-Office@ouhsc.edu
Ingrid Block
4052718777
SCC-IIT-Office@ouhsc.edu
SCC IIT Office
405-271-8777
SCC-IIT-Office@ouhsc.edu
Stephenson Cancer Center
Interventions
  • Device: PARASYM neuromodulation device — Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
  • Device: PARASYM neuromodulation device — Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the "experimental arm" for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
Study Locations (2 sites)
Stephenson Cancer Center, Oklahoma City, Oklahoma 73104 United States
Stephenson Cancer Center- Tulsa, Tulsa, Oklahoma 74104 United States
Eligibility Criteria
Inclusion Criteria: * Patients (\>18 years) who have received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days * A least 1 of following additional criteria: * previous chest radiation . Age\>50 * type 2 diabetes mellitus * hypertension * current smoking * obesity (BMI ≥ 30) * previous myocardial infarction * established atherosclerotic heart disease or significant valve disease. chronic kidney disease Exclusion Criteria: * Atrial paced rhythm * History of seizure currently on treatment * History of vasovagal syncope * End stage liver or kidney disease
Conditions Breast Cancer Triple Negative, Breast Ca...
Phase Not Applicable
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in the cytokine milieu in the blood (From baseline within 24 hours of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-05-30
Completion: 2028-02-20
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Ruth Sacks, MD (PRINCIPAL_INVESTIGATOR) - Emory University Hospital/Winship Cancer Institute
Contact Information
Study Contact:
Ruth Sacks, MD
404-778-1900
rlsacks@emory.edu
Ashley Trumbull
404-778-3969
ashley.lynn.trumbull@emory.edu
Emory University/Winship Cancer Institute
Ruth Sacks, MD
Emory University/Winship Cancer Institute
Interventions
N/A
Study Locations (1 sites)
Emory University/Winship Cancer Institute, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed, previously untreated, non-metastatic Stage II-III invasive breast cancer * Estrogen receptor IHC expression ≤10%; progesterone receptor IHC expression ≤ 10%; HER2 negative * HER2 negativity is defined as either of the following by local laboratory assessment: * IHC 0, 1+, or 2+ and In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 \<2.0 or single probe average HER2 gene copy number \<4 signals/cell) * No prior chemotherapy, endocrine therapy, or immunotherapy * Willingness and ability of the subject to comply with scheduled visits, standard of care drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions. * Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study * Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs. * Patients on steroid medications (i.e. prednisone, dexamethasone, etc.) that are not part of the standard pre-medications and/or take home medications that are included as a part of medication regimen for the pre-operative chemo-immunotherapy described in the study. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study agents. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
Conditions Diabetes Mellitus, Non Insulin Dependent...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This goal of this NIH funded R01 study is to identify risk factors for not being able to follow-up for a new diagnosis of diabetes in the emergency department and improve linkage of these newly diagnosed patients to appropriate outpatient care. Its three aims will be accomplished through 1) a retrospective chart review of emergency department (ED) patients screened for diabetes, 2) a series of prospective qualitative interviews among ED patients with newly diagnosed diabetes who fail to follow-up for outpatient care, and 3) a simple randomized controlled trial to test the efficacy of telehealth bridge visits to connect ED patients with newly diagnosed diabetes to outpatient primary care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Other: Telehealth Bridge Visits — Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
  • Other: Standard of Care — Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.

Primary Outcomes

  • Percent of Patients who Complete at least One In-Person Follow-up Outpatient Visit (Up to Month 6 Post-Diagnosis)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-01
Completion: 2028-05-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • David C. Lee (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
David C. Lee
212-562-6561
David.Lee@nyulangone.org
Interventions
  • Other: Telehealth Bridge Visits — Patients will be scheduled for a telemedicine visit staffed by a family or internal medicine trained physician who will assess their understanding and answer any questions about the new diagnosis of diabetes, start initial conversations about how to improve their habits around diet and exercise, and discuss medication options for diabetes and, if appropriate, initiate treatment. At the end of the telemedicine visit, providers will attempt to address any difficulties that patients are experiencing in accessing primary care by providing an alternative contact for care or reaching out to a primary care doctor as necessary. If the patient experiences difficulties accessing a primary care provider based on their first telemedicine visit, then an additional telemedicine visit can be scheduled for the patient.
  • Other: Standard of Care — Standard of care currently includes calls from the site's follow-up center to see if patients received their HbA1c result, understood what their result meant, had any problems accessing medications prescribed or any difficulty scheduling an outpatient follow-up visit.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria: * Emergency patient receiving lab tests with an initial HbA1c test result of ≥ 6.5% * Residential address in New York City or Long Island * Primary language is English or Spanish * Able to provide informed consent Exclusion Criteria: * No prior history of diabetes * No medical condition that would result in a spurious HbA1c test (e.g., sickle cell, recent blood loss)
Conditions Major Depressive Episode
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite international efforts to identify biomarkers of depression, none has been transferred to clinical practice, neither for diagnosis, evolution, nor therapeutic response. This led us to build a French national cohort (through the clinical and research network named SoPsy within the French biological psychiatry society (AFPBN) and sleep society (SFRMS)), to better identify markers of sleep and biological rhythms and validate more homogeneous subgroups of patients, but also to specify the manifestations and pathogeneses of depressive disorders.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • amount of REM sleep (at inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-01
Completion: 2033-05-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: Not specified
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Pierre Alexis GEOFFROY, PU-PH
01 40 25 82 62
Pierrealexis.geoffroy@aphp.fr
Julia MARUANI
julia.maruani@aphp.fr
Interventions
N/A
Study Locations (1 sites)
Hôpital Bichat Claude Bernard, Paris, Paris 75018 France
Eligibility Criteria
Inclusion Criteria: * Individuals with depressive episode characterized according to the DSM-5 criteria regardless of the associated characteristics and comorbidities. * Adult and child * Affiliated to a social security Exclusion Criteria: * don't understand or read french * Medical condition incompatible with administration of questionnaire * impossibility to give informed decision (subject in an emergency condition, etc.)
Conditions Treatment Resistant Depression (TRD)
Phase NA
Enrollment 166
Locations 24 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide. Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption. Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients. The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response. The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry. The DepVNS hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment. The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Vagus Nerve Stimulation (VNS) — The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
  • Other: Best Medical Treatment — Best Medical Treatment for resistant depression.

Primary Outcomes

  • Cost-utility of VNS (Month 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-19
Completion: 2033-02-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 166 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: LivaNova
Principal Investigators:
  • Philippe DOMENECH, MD, MSc (STUDY_DIRECTOR) - GHU Paris Psychiatrie & Neurosciences (site Sainte-Anne)
Contact Information
Study Contact:
Philippe DOMENECH, MD, MSc
(0) 1 45 65 76 65
philippe.domenech@ghu-paris.fr
Fabien VINCKIER, MD, MSc
(0) 1 45 65 84 52
f.vinckier@ghu-paris.fr
Thomas BIENVENU, Dr
06 49 92 02 45
tbienvenu@ch-perrens.fr
Centre Hospitalier Charles Perrens
Interventions
  • Device: Vagus Nerve Stimulation (VNS) — The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
  • Other: Best Medical Treatment — Best Medical Treatment for resistant depression.
Study Locations (24 sites)
CHU Angers, Angers, France 49933 France
Centre Hospitalier Charles Perrens, Bordeaux, France 33076 France
CHU Caen, Caen, France 14000 France
CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France 63000 France
AP-HP. Nord - Université de Paris, Hôpital Louis Mourier, Colombes, France 92700 France
APHP. Hôpitaux Universitaires Henri Mondor, Hôpital Henri Mondor, Créteil, France 94000 France
CHU Dijon, Hôpital Le Bocage, Dijon, France 21000 France
CHU Grenoble Alpes, Grenoble, France 38700 France
AP-HP. Université Paris Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France 94270 France
CHU Lille, Lille, France 59037 France
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and older ; * Childbearing women must have an efficient contraception for the whole study period * Diagnosis of recurrent depressive trouble or persistent depressive disorder or bipolar disorder (according to DSM-5) * Start of disorder (defined by the occurrence of the first thymus episode: characterized depressive disorder or maniac episode with or without mixed characteristics) for 5 years or more * At least one of the following criteria: * Criterion A: current characterized depressive disorder and characterized depressive disorder for at least 12 months during the last 24 months despite at least four treatments lines at appropriate dosage and duration * Criterion B: current treatment by ECT/(Es)Ketamine/TMS and criteria A before the start treatment or ECT/(Es)Ketamine/TMS dependency * Patients who, after the nature of the study has been explained to them, have given written consent Exclusion Criteria: * Know pregnancy or breastfeeding * Schizophrenia, schizoaffective disorder or persistent delusional disorder (DSM-5) * Characterized depressive disorder with psychotic characteristics within 3 months before the inclusion (DSM-5) * Concomitant participation to another interventional research not authorized by the coordinating investigator or the scientific lead. Participation to non-interventional researches is allowed. * Patients receiving enforced cares (ASPDT, ASPPI, ASPDRE, etc.) * Non-affiliation to a social security regimen or any other social protection regimen * Disability, according to the investigator, to understand the study or refusal to sign the study consent form (non-francophone patient, cognitive disorders) * Anticipated disability to attend all the visits, treatments and measures planned by the protocol: severe personality disorder, severe substance addiction, severe intellectual development disorder. In any of those cases, the notion of severity is at the indiscretion of the investigator Secondary Exclusion Criteria: * Surgical contraindication to the VNS * Positive β-HCG (results obtained after the informed consent is signed but before the randomization)
Conditions Palliative Care, Pain, Anxiety, Depressi...
Phase PHASE2
Enrollment 60
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects. Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Lysergic Acid Diethylamide Tartrate — 25 μg p.o.
  • Drug: Lysergic Acid Diethylamide Tartrate — 100 or 200 μg p.o.

Primary Outcomes

  • Changes in state anxiety assessed by questionnaire (state anxiety inventory, STAI-S) compared with active placebo (baseline, 2 weeks after second intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-06-09
Completion: 2028-05
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Collaborators: University Hospital, Zürich, Spital Uster AG, Uster, Switzerland, University Hospital, Geneva
Principal Investigators:
  • Yasmin Schmid, PD Dr. med. (PRINCIPAL_INVESTIGATOR) - University Hospital, Basel, Switzerland
Contact Information
Study Contact:
Yasmin Schmid, PD Dr. med.
: +41 61 328 68 47
yasmin.schmid@usb.ch
Yasmin Schmid, PD Dr. med.
+41 61 328 68 47
yasmin.schmid@usb.ch
University Hospital Basel, Division of Clinical Pharmacology and Toxicology
Melani Zupari, MSc
+41 61 328 77 42
melani.zuparic@usb.ch
University Hospital Basel, Division of Clinical Pharmacology and Toxicology
Interventions
  • Drug: Lysergic Acid Diethylamide Tartrate — 25 μg p.o.
  • Drug: Lysergic Acid Diethylamide Tartrate — 100 or 200 μg p.o.
Study Locations (4 sites)
University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, 4031 Switzerland
University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, 1245 Switzerland
Spital Uster AG, Division of Internal Medicine, Uster, 8610 Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: * Age ≥ 22 years. * Advanced or End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years * Sufficient understanding of the study procedures and risks associated with the study. * Participants must be willing to adhere to the study procedures and sign the consent form. * Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration. * Participants must complete an actual "Emergency Medical Directive" * Participants with central nervous system (CNS) involvement of cancer are eligible if the following apply: * treated and stable CNS lesion(s) OR untreated but asymptomatic/stable lesions, defined as clinically and/or radiologically stable for ≥ 4 weeks before screening * no seizures within ≥ 4 weeks; if on antiepileptic medication: stable dose ≥ 4 weeks and no relevant drug-drug interactions expected * no requirement for high-dose corticosteroids, defined as ≤10 mg prednisone equivalent per day on a stable or decreasing dose * no leptomeningeal metastases * no concomitant therapeutic anticoagulation Exclusion Criteria: * Life expectancy \&lt; 12 weeks * Known hypersensitivity to LSD * Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period. * Current use of a potent drug CYP2D6 inhibitor * Women who are pregnant or nursing or intend to become pregnant during the course of the study. * Somatic disorders including CNS involvement of cancer, untreated epilepsy with a history of generalized grand-mal seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects. * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant. * Participation in another study with an investigational drug within the 30 days preceding and during the present study * concomitant diagnosis of past or present psychotic disorder, first-degree relative with psychotic disorders * concomitant diagnosis of past or present bipolar disorder * current delirium * substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety). * Weight \&lt; 45 kg * Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator. * CNS involvement of cancer if * CNS disease is unstable or high-risk, including clinically and/or radiologically progressive lesions, signs of raised intracranial pressure, radiologically uncontrolled edema, need for escalating corticosteroid doses, or any neurological condition judged to pose too excessive risk. * CNS-directed therapy (surgery and/or radiation) within ≤ 4 weeks
Conditions Severe Traumatic Brain Injury, Intracran...
Phase NA
Enrollment 30
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this phase 1 randomized controlled safety and feasibility clinical trial are to determine the safety of external lumbar drainage (ELD) in select patients with severe Traumatic Brain Injury (TBI). The main questions it aims to answer are (i) if ELD is feasible and (ii) safe to perform in severe TBI patients who have radiological evidence of patent basal cisterns and midline shift \<5mm without increasing the risk of neurological worsening or cerebral herniation. All participants will receive routine usual care. The study group will additionally have ELD for cerebrospinal fluid (CSF) drainage. A comparison will be made between the usual treatment plus ELD (interventional) groups, and the usual treatment (control) groups on incidence rate of neurological worsening or cerebral herniation events, and whether total hours with raised intracranial pressure (ICP) are different.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: External Lumbar drainage — ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage

Primary Outcomes

  • Safety of ELD in selected Severe TBI patients (10 days)
  • Feasibility of ELD in selected Severe TBI patients (10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-24
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brain Trauma Foundation
Collaborators: Uniformed Services University of the Health Sciences, University of Kansas, The Cleveland Clinic, Weill Medical College of Cornell University
Principal Investigators:
  • Halinder S Mangat, MD MSc (PRINCIPAL_INVESTIGATOR) - Brain Trauma Foundation; Kansas University Medical Center Research Institute
  • Jamshid Ghajar, MD PhD (PRINCIPAL_INVESTIGATOR) - Brain Trauma Foundation
  • Gregory Hawryluk, MD PhD (PRINCIPAL_INVESTIGATOR) - Cleveland Clinic Foundation, Brain Trauma Foundation
Contact Information
Study Contact:
Carlos Morales, MPH
240-6536638
carlos.morales.ctr@usuhs.edu
Halinder S Mangat, MD, MSc
913-5886970
elastic@braintrauma.org
Ivan DaSilva, MD
Ivan.RochaFerreiraDaSilva@neurology.ufl.edu
University of Florida
Interventions
  • Procedure: External Lumbar drainage — ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
Study Locations (6 sites)
University of Florida, Gainesville, Florida 32610 United States
Kansas University Medical Center, Kansas City, Kansas 66160 United States
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Brooke Army Medical Center, Fort Sam Houston, Texas 78234 United States
University of Houston Medical Center, Houston, Texas 77030 United States
University of Texas, San Antonio, Texas 78249 United States
Eligibility Criteria
Inclusion Criteria: 1. 18-65 years age 2. Glasgow Coma Scale (GCS) 3-8 3. Pupils symmetric and bilaterally reactive 4. Midline shift ≤5mm at the level of foramen of Monro on admission or post-operative brain CT 5. Patent (complete or partial) quadrigeminal cisterns on admission or post-operative brain CT 6. First randomization and intervention may be commenced within 24 hours of injury 7. ELD safety score ≥5 Exclusion Criteria: 1. GCS \>8 2. Cisterns on CT completely effaced 3. Midline shift on CT \>5mm 4. GCS 3 with dilated and fixed pupils 5. Uncal or tonsillar herniation on admission or post-operative brain CT 6. Temporal lobe contusions with effaced ipsilateral cisterns 7. Penetrating TBI 8. Primary hemicraniectomy 9. Pregnancy 10. Prisoners 11. Patients previously lacking capacity to consent or refuse treatment, or with advanced directives to forego aggressive care 12. Pre-existing conditions affecting functional status or life expectancy to less than 1 year 13. Contra-indications for ELD placement: coagulopathy, use of anticoagulants or anti-thrombotics, thrombocytopenia \<50,000, or severe spinal deformity. 14. posterior fossa hemorrhage
Conditions Depression, Suicidal Ideation, Major Dep...
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators hypothesized that during the 9-week course of Engage \& Connect treatment there will be an increase in brain functions of the Positive Valence System which in turn will lead to reduction in suicidality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: "Engage & Connect" Psychotherapy — 9-weeks of weekly psychotherapy sessions focused on social reward exposure
  • Behavioral: Symptom Review and Psychoeducation (SRP) — 9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging

Primary Outcomes

  • Change in resting state functional connectivity of the Positive Valence System (Baseline, midtreatment (week 6) and post treatment (week 9))
  • Change in STAR task reaction time following social feedback (Baseline, midtreatment (week 6), and post treatment (week 9))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-18
Completion: 2028-09-30
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Nili Solomonov, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Nili Solomonov, PhD
(914) 682-9100
nis2051@med.cornell.edu
Nili Solomonov, PhD
844-999-8746
nis2051@med.cornell.edu
Weill Cornell Medicine
Nili Solomonov, PhD
Weill Cornell Medicine
Interventions
  • Behavioral: "Engage & Connect" Psychotherapy — 9-weeks of weekly psychotherapy sessions focused on social reward exposure
  • Behavioral: Symptom Review and Psychoeducation (SRP) — 9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Ages aged 50-80 \[stratified so that 50% are older than 65\] * Endorsement of Suicidal Ideation \[Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-5 (SCID-5) Suicide Item (Item 9) with a score of 2 * Major Depressive Disorder as determined by the SCID-5 * Depression Rating Scale \[Montgomery-Åsberg Depression Rating Scale (MADRS)\] score of 16 or greater. * Mini Mental Status Exam (MMSE) equal or greater than a score of 23 * Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 10 weeks, without individual psychotherapy services during the study period. * Capacity to provide consent for research assessment and treatment. Exclusion Criteria: * Intent or plan to attempt suicide in the near future. * History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, generalized anxiety disorder, or specific phobia. * Use of psychotropic drugs or cholinesterase inhibitors other than use of 0.5 mg or less of lorazepam daily up to seven times per week. * Neurological disorders (dementias, amnestic and multidomain Mild Cognitive Impairment, Parkinson's disease, epilepsy, etc.). * Acute or severe medical illness in the past 3 months (metastatic cancer, multiple sclerosis, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction, cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease, etc.) that may be the primary cause depressive symptoms, influence brain systems of interest, or impact ability to participate in the study. * Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, insulin pump, cochlear implant, any other metallic biomedical implant contraindicating to MRI, and claustrophobia.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 352
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To de-escalate radiation therapy in women with breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Ipsilateral breast tumour recurrence (IBTR) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-12
Completion: 2031-10
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 352 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborators: Canadian Institutes of Health Research (CIHR), Hamilton Health Sciences Corporation
Principal Investigators:
  • Elena Parvez, MD (PRINCIPAL_INVESTIGATOR) - Juravinski Cancer Centre
  • Thierry Muanza, MD (PRINCIPAL_INVESTIGATOR) - Jewish General Hospital
  • Mark Basik, MD (PRINCIPAL_INVESTIGATOR) - Jewish General Hospital
Contact Information
Study Contact:
Adrianne Van Dam
905-527-2299
avandam@mcmaster.ca
Rachael Rowse
rachael.rowse@health.nsw.gov.au
Tweed Valley Hospital
Katherina Farr, Dr
Tweed Valley Hospital
Interventions
N/A
Study Locations (27 sites)
Tweed Valley Hospital, Cudgen, Cudgen 2487 Australia
Liverpool Hospital, Liverpool, New South Wales 1871 Australia
Mater Hospital Sydney, North Sydney, New South Wales 2060 Australia
Westmead Hospital, Westmead, New South Wales 2145 Australia
Royal Brisbane and Women's Hospital, Herston, Queensland 4029 Australia
Princess Alexandra Hospital, Woolloongabba, Queensland 4102 Australia
Monash Medical Centre -Moorabbin, Bentleigh East, Victoria 3165 Australia
Victorian Breast & Oncology Care (VBOC), East Melbourne, Victoria 3002 Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria 3000 Australia
St. Vincent's Hospital Melbourne, Melbourne, Victoria 3065 Australia
Eligibility Criteria
Inclusion Criteria: 1. Female patient with a new histological diagnosis of clinical T1-3 N0 breast cancer (any tumour sub-type). 2. Negative lymph node involvement at initial presentation, documented by imaging (US or MRI), fine needle aspiration (FNA) or core needle biopsy. 3. Treated with a minimum of 8 weeks NAC, with patients with Her2+ disease receiving targeted anti-Her2+ therapy. 4. Marker clip placed in the tumour bed prior to or during neoadjuvant chemotherapy when the tumour can still be identified. 5. Treated by BCS with complete excision of the tumour bed and axillary staging surgery (either sentinel lymph node biopsy or axillary lymph node dissection). 6. Final pathology demonstrating a pCR \[defined as absence of residual invasive and in-situ breast cancer within the breast or lymph nodes (ypT0N0)\]. Exclusion Criteria: 1. Age less than 50 years. 2. Inflammatory breast cancer or breast cancer invading the skin or chest wall (T4 disease). 3. Multicentric disease (i.e., breast cancer involving more than one quadrant in the same breast). 4. Prior history of ipsilateral or contralateral in-situ or invasive breast cancer. Patients with a history of lobular carcinoma in-situ (LCIS) are ineligible. 5. Synchronous contralateral in-situ or invasive breast cancer. 6. BRCA (breast cancer gene) 1 or 2 genetic mutation carrier, or other genetic mutation present associated with increased risk of breast cancer. 7. Other previous non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers or other cancers curatively treated with no evidence of disease for ≥ 5 years. 8. Inability to complete entire course of neoadjuvant therapy (minimum of 8 weeks of treatment). 9. Patients with HR+ (hormone receptor) disease who are not planned to have endocrine therapy initiated. 10. Patients with Her2+ disease who have not received or are not planned to receive Her2 targeted therapy. 11. ECOG (Eastern Cooperative Oncology Group) performance status \> 3. 12. Inability to provide informed consent.